Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
|Articles|December 2, 2002
- Pharmaceutical Technology-12-02-2002
- Volume 26
- Issue 12
Sensitivity of Gelatin Raw Materials to Cross-Linking: The Influence of Bloom Strength, Type, and Source
Author(s)Saranjit Singh
The authors recount the findings of a study that examined the sensitivity of cross-linked gelatin materials to variables such as bloom strength, type, and source.
Advertisement
Articles in this issue
almost 24 years ago
Generic Drugs Take Center Stagealmost 24 years ago
Contract Servicesalmost 24 years ago
Fifth Annual International Employment Surveyalmost 24 years ago
Determination by Analytical Sieving: Particle-Size Distribution, Part IIIAdvertisement
Related to this article
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
5